Abstract
The FDA Modernization Act 2.0 allows bioengineered models in drug testing, including benchtop testing and computational models. These alternatives to animal testing may particularly advance drug discovery in reproductive and pregnancy research.
| Original language | English |
|---|---|
| Article number | 14584 |
| Pages (from-to) | 984-986 |
| Number of pages | 3 |
| Journal | Nature Reviews Bioengineering |
| Volume | 2 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Dec 2024 |
Bibliographical note
Publisher Copyright:© Springer Nature Limited 2024.
Funding
S.G.Z. and A.K.S. report financial support provided by the US National Institutes of Health. M.L.O. reports financial support provided by Wellcome Leap in Utero. This paper was funded by the T32 Clinical Outcomes Research Training Program in Female Lower Urinary Tract Disorders, US National Institutes of Health grant T32DK120497 (S.G.Z.). The authors would also like to acknowledge a US National Institutes of Health T32 Postdoctoral Training Grant in Regenerative Medicine (T32EB028092) for additional research support (A.K.S.).
| Funders | Funder number |
|---|---|
| Wellcome Leap in Utero | |
| National Institutes of Health (NIH) | T32EB028092, T32DK120497 |
| National Institutes of Health (NIH) |
ASJC Scopus subject areas
- Biophysics
- Biomedical Engineering
- Applied Microbiology and Biotechnology